{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"}],"units":"Participants"}],"description":"Objective response rate is the proportion of subjects in the efficacy-evaluable set with radiologically confirmed measurable disease at baseline, who achieved partial response (PR) or better after infusion as determined by RECIST 1.1. Missing or non-evaluable time points will not be included.\n\nPer RECIST 1.1, a complete response is defined as \"disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm.\" A partial response is defined as \"at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.\"","groups":[{"description":"Single dose of 1-3x10\\^7 huCARTmeso cells/m\\^2\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG000","title":"Cohort 1"},{"description":"Cyclophosphamide 1 gram/m\\^2 administered 2-4 days prior to a single dose of 1-3x10\\^7 huCARTmeso cells/m\\^2\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG001","title":"Cohort 2"},{"description":"PERMANENTLY CLOSED\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG002","title":"Cohort 3"},{"description":"PERMANENTLY CLOSED\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG003","title":"Cohort 4"},{"description":"Single dose of 1-3x10\\^7 huCART-meso cells/m\\^2 day 0 by intrapleural infusion (IP) through an indwelling pleural catheter without any conditioning chemotherapeutic regimen.\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG004","title":"Cohort 5"},{"description":"Cyclophosphamide 1 gram/m\\^2 administered 2-4 days prior to dose of 1-3x10\\^7 huCART-meso cells/m\\^2 via IV infusion on Day 0. This initial infusion may be followed by up to two additional IV infusions of huCART-meso cells at the same dose level, given approximately 21-42 days apart, if the subject meets eligibility to receive additional infusions. Cyclophosphamide will not be repeated prior to subsequent doses of huCART-meso cells.\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG005","title":"Cohort 6"},{"description":"Cyclophosphamide 300 mg/m\\^2/day and fludarabine 30 mg/m\\^2/day given over 3 days by IV infusion followed by a single dose of 1-3x10\\^7 huCART-meso cells/m\\^2 via intraperitoneal (i.p.) administration. Lymphodepleting chemotherapy will be scheduled such that the last day of chemotherapy is 3 days (+/- 1 day) prior to the infusion of huCART-meso cells. This initial i.p. infusion may be followed by up to two additional infusions of huCART-meso cells via intravenous (IV) administration at the same dose level, given between 21-42 days apart. The subject must meet eligibility to receive additional infusions. Lymphodepleting chemotherapy will not be repeated prior to additional infusions of huCART-meso cells.\n\nhuCART-meso cells: Intravenous administration or local delivery of lentiviral transduced huCART-meso cells in 7 cohorts with or without lymphodepletion..","id":"OG006","title":"Cohort 7"}],"paramType":"NUMBER","populationDescription":"Cohort 4 was permanently closed.","reportingStatus":"POSTED","timeFrame":"Month 6","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}